Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03607838 · ClinicalTrials.gov registry record · Phase 3
SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)
A Phase 3 study, sponsored by Seikagaku Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 352
- Enrollment target
NCT03607838 is a Phase 3 study that has completed, run by Seikagaku Corporation. The registered enrollment target is 352 participants.
The verdict
NCT03607838, a Phase 3 study, has completed, sponsored by Seikagaku Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 352 participants
- Enrollment target
Study Summary
This study is to evaluate the effectiveness of a single-dose intervertebral disc injection of SI-6603 in subjects with lumbar disc herniation (LDH)
Interventions
- DRUG Sham injection
- DRUG SI-6603
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2018-11-07 |
| Est. Completion | 2023-03-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03607838
The ClinicalTrials.gov registry entry for NCT03607838 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 352 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seikagaku Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham injection is the first listed.
NCT03607838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03607838 about?
NCT03607838 is a clinical study titled "SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)". This study is to evaluate the effectiveness of a single-dose intervertebral disc injection of SI-6603 in subjects with lumbar disc herniation (LDH)
What is the current status of trial NCT03607838?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 352 participants. The study started on 2018-11-07. Estimated completion is 2023-03-21.
What interventions are being tested in trial NCT03607838?
The interventions under investigation include: Sham injection (DRUG), SI-6603 (DRUG).
Who is sponsoring clinical trial NCT03607838?
This trial is sponsored by Seikagaku Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.